The impact of different HRT regimens on compliance

International Journal of Fertility and Menopausal Studies

Volumn 41, Issue 1, 1996, Pages 29-39

  Dören, Martina ^a,b   Schneider, H P G ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

bleeding; compliance; hormone replacement therapy; postmenopausal regimens

Indexed keywords

CYPROTERONE ACETATE; ESTRADIOL; ESTROGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NORETHISTERONE ACETATE; NORGESTREL; TIBOLONE;

CONFERENCE PAPER; DECISION MAKING; EDUCATION PROGRAM; ENDOMETRIUM ATROPHY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; VAGINA BLEEDING;

EID: 0029981289     PISSN: 10693130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Falkeborn M; Persson Ix Adami HO, et al: Risk of acute myocardial infarction after estrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 99:821-828, 1992.
2. Finucane FF, Madans JH, Bush TL, et al: Decreased risk of stroke among postmenopausal hormone users. Arch Int Med 153:73-79, 1993.
3. Oddens BJ, Boulet MJ, Lehert P, et al: Has the climacteric been medicalized? A study on the use of medication for climacteric complaints in four countries. Maturitas 15:171-181, 1992.
4. Cano A: Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 20:91-99, 1995.
5. Blackwell B: Compliance. Psychother Psychosom 58:161-169, 1992.
6. Ferguson KJ, Hoegh C, Johnson S: Estrogen replacement therapy. A survey of women's knowledge and attitudes. Arch Intern Med 149:133-136, 1989.
7. Nachtigall LE: Enhancing patient compliance with hormonal replacement therapy at menopause. Obstet Gynecol 75:877-80, 1990.
8. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:589-593, 1995.
9. Stamford JL,. Weiss NS, Voigt LF, et al: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274:137-142, 1995.
10. Rodriguez C, Galle EE, Coates RJ, et al: Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 141:828-835, 1995.
11. Calle EE, Coates RJ, Miracle-McMahill HL, et al: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. JNatl Cancer Inst 87:517-523, 1995.
12. Miller VT, Barnabei V, Kessler C, et al: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 273:199-208, 1995.
13. Whitehead MI, Hillard TC, Crook D: The role and use of progestogens. Obstet Gynecol 75:559-76, 1990.
14. Staland B: Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 3:145-156, 1981.
15. Mattson L-A, Cullberg G, Samsioe G: Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 4:95-102, 1982.
16. Dören M, Reuther G, Minne HW, Schneider HPG: Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 173:1446-1451, 1995.
17. Sporrong T, Hellgren M, Samsioe G, et al: Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints. Br J Obstet Gynaecol 95:1042-1048, 1988.
18. Marslew U, Riis BJ, Christiansen C: Bleeding patterns during continuous combined estrogen-progestogen therapy. Am J Obstet Gynecol 164:1163-1168, 1991.
19. Munk-Jensen N, Ulrich LG, Obéi EB, et al: Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect on plasma lipoproteins in a two-year placebocontrolled trial. Am J Obstet Gynecol 71:132-138, 1994.
20. Christiansen C, Riis BJ: Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol 97:1087-1092, 1990.
21. Nielsen SP, Barenholdt O, Hermansen F, et al: Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. BiJ Obstet Gynaecol 101:319-24, 1994.
22. Weinstein L, Bewtra C, Gallagher JC: Evaluation of a continuous combined low-dose regimen of estrogenprogestin for treatment of the menopausal patient. Am J Obstet Gynecol 162:1534-1542, 1990.
23. Fuleihan GE, Brown EM, Curtis K, et al: Effect of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism. Arch IntMed 152:1904-1909, 1992.
24. Luciano AA, De Souza MJ, Roy MF, et al: Evaluation of low-dose estrogen and progestin therapy in postmenopausal women. J Repwd Med 38:207-214, 1993.
25. Archer DF, Pickar JH, Bottiglioni F for the Menopause Study Group: Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 83:686-692, 1994.
26. Hillard TC, Siddle NC, Whitehead MI, et al: Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologie diagnosis. Am J Obstet Gynecol 167:1-7, 1992.
27. Magos AL, Brincat M, Studd JWW, et al: Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 65:496-499, 1985.
28. Hillard TC, Siddle NC, Whitehead MI, et al: Continuous combined conjugated estrogen/progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologie diagnosis. Am J Obstet Gynecol 167:1-7, 1992.
29. Hargrove JT, Maxson WS, Wentz AC, et al: Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 73:606-612, 1989.
30. Andersen K, Mattson L-M, Rybo G, et al: Intrauterine release of levonorgestrel-a new way of adding pro-
31. gestogen in hormone replacement therapy. Obstet Gynecol 79:963-967, 1992.
32. Nand SL, Webster MA, Wren BG: Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy-a study of bleeding pattern, endometrial response, serum lipid and bone density changes. Aust NZ J Obstet Gynaecol 35:92-96, 1995.
33. Woodruff JD, Pickar JH for the Menopause Study Group: Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 170:1213-1223, 1994.
34. Polvani F, Zichella L, Bocci A, et al: A randomized comparative study for the clinical evaluation of hormone replacement by transdermal and oral routes. Clin Exp Obstet Gynecol 17:207-213, 1991.
35. Hillard TC, Whitcroft SJ, Marsh MS, et al: Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis Int 4:341-348, 1994.
36. Stevenson JC, Crook D, Godsland IF, et al: Oral versus transdermal hormone replacement therapy. Int J Fertil 38:S30-35, 1993.
37. Erenus M, Kutlay K, Kutlay L, et al: Comparison of the impact of oral versus transdermal estrogen on serum lipoproteins. Feitil Steril 61:300-302, 1994.
38. Grey AB, Cundy TF, Reif IR: Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. Clin Endocrinol 40:671677, 1994.
39. Casper RF, Chapdelaine A: Estrogen and interrupted progestin: a new concept for menopausal hormone replacement therapy. Am J Obstet Gynecol 168:11881196, 1993.
40. Ettinger B, Selby }, Citron JT, et al: Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 83:5693-700, 194.
41. Williams DB, Boigt BH, et al: Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol 84:787-793, 1994.
42. Rymer J, Fogelman I, Chapman MG: The incidence of vaginal bleeding with tibolone treatment. Bi J Obstet Gyencol 101:53-56, 1994.
43. Van Dadelszen P, Gillmern MDG, Gray MD, et al: Endometrial hyperplasia and adenocarcinoma during tibolone (Livial) therapy. Br J Obstet Gynaecol 101:158-161, 1994.
44. Sporrong T, Samsioe G, Larsen S, Mattson L-A: A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy. Maturitas 11:209-215, 1989.
45. Leather AT, Sawas M, Studd JWW: Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 78:10081010, 1991.
46. Goodman L, Awwad J, Marc K, et al: Continuous combined hormonal replacement therapy and the risk of endometrial cancer-preliminary report. Menopause 1:57-59, 1994.
47. Lin MC, Gosnik BB, Wolf SI, et al: Endometrial thickness after menopause: effect of hormone replacement. Radiology 180:427-32, 1991.
48. Wiklund I, Karlberg J, Mattson L-M: Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 168:824-830, 1993.
49. Rubin SM, Cummings ST: Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Int Med 116:990-995, 1992.
50. Ryan PJ, Harrison R, Blake GM, et al: Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 99:325-328, 1992.